Hydrocortisone topical: Difference between revisions

(Switch SMW query from broadtable to table format for better layout with TOC)
 
(3 intermediate revisions by 2 users not shown)
Line 52: Line 52:
*Excretion: urine
*Excretion: urine
*Mechanism of Action: exact mechanim of anti-inflammatory action unknown; inhibits multiple inflammatory cytokines; produces multiple gluocorticoid and mineralocorticoid effects
*Mechanism of Action: exact mechanim of anti-inflammatory action unknown; inhibits multiple inflammatory cytokines; produces multiple gluocorticoid and mineralocorticoid effects
==Indications by Condition==
''The following table is automatically generated from disease/condition pages across WikEM.''
{{#ask:[[Has DrugName::Hydrocortisone]]
|?Has Indication=Indication
|?Has Dose=Dose
|?Has Context=Context
|?Has Route=Route
|?Has Population=Population
|format=table
|headers=plain
|mainlabel=-
|sort=Has Indication
|limit=50
}}


==See Also==
==See Also==
*[[Stress dose steroids]]
*[[Stress dose steroids]]
*[[Hydrocortisone (systemic)]]


==References==
==References==

Latest revision as of 21:56, 20 March 2026

General

  • Type: Topical steroid
  • Dosage Forms: 0.5%, 1%, 2.5% crm, lotion, oint
  • Common Trade Names: Cortizone, Cortaid, Hytone, Texacort

Adult Dosing

Dermatoses, steroid-responsive

  • Apply bid-QID

Pediatric Dosing

Dermatoses, steroid-responsive

  • Apply bid-QID

Special Populations

  • Pregnancy Rating: C
  • Lactation: Excretion in milk unknown; use with caution
  • Renal Dosing: None
  • Hepatic Dosing: None

Contraindications

  • Allergy to class/drug
  • caution if skin infection
  • caution in pediatric patients

Adverse Reactions

Serious

  • HPA axis suppresion
  • Cushing syndrome
  • hyperglycemia
  • intracranial hypertension (pediatric patients)

Common

  • burning
  • pruritus
  • irritation
  • dryness
  • folliculitis
  • hypertrichosis
  • acneiform dermatitis
  • hypopigmentation
  • perioral dermatitis
  • allergic contact dermatitis
  • maceration
  • secondary infection
  • skin atrophy
  • striae
  • miliaria

Pharmacology

  • Half-life: 8-12h
  • Metabolism: liver primarily; CYP450
  • Excretion: urine
  • Mechanism of Action: exact mechanim of anti-inflammatory action unknown; inhibits multiple inflammatory cytokines; produces multiple gluocorticoid and mineralocorticoid effects


Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
COPD exacerbation100-125 mg IV q6h x5 daysCorticosteroid (IV option)IVAdult
Pituitary apoplexy100-200mg IV bolus, then 2-4mg/hr infusionStress-dose corticosteroid replacementIVAdult
Sepsis (main)50 mg IV q6h (200 mg/day)Stress dose steroids for septic shockIVAdult
Thyroid storm300 mg IV bolus, then 100 mg IV TIDAdrenal insufficiency treatment + T4→T3 blockadeIVAdult
Toxic megacolon100mg q6hrAnti-inflammatory for underlying IBDIVAdult

See Also

References